Artificial intelligence (AI) has significantly transformed cardiovascular drug development and approval. Cardiovascular diseases are complex, chronic, and multifactorial, making them well suited for data-driven drug discovery and development. AI is now integrated across all stages of cardiovascular drug development, from research and clinical trials to post-approval patient management. Beyond reducing costs, AI can improve the precision of cardiovascular therapies, enhance drug safety, and support better long-term outcomes.
Report Includes
- Impact analysis of artificial intelligence (AI) on the Cardiovascular Drugs Market
- Case studies for successful integration of AI in increased efficiency of drug discovery, accelerated clinical trial process, and improved patient outcome
- Highlights of AI’s impact across the major geographic regions and end-user industries
- Review of disruptions caused by AI across key industry verticals and the impact on various stages of global supply chain
- Competitive landscape featuring strategic initiatives, market spendings and VC funding outlook
Table of Contents
Chapter 1 Key Use Cases for AI Implementation- Overview
- Key Use Cases
- Use Case 1: Clinical Trial Optimization
- Use Case 2: Real-World Patient Monitoring
- Use Case 3: Personalized Treatment and Patient Engagement
- Use Case 4: Pharmacovigilance and Safety Surveillance
- Overview
- Adoption Trends by Region
- Adoption Trends in North America
- Adoption Trends in Europe
- Adoption Trends in Asia-Pacific
- Adoption Trends in the Rest of the World
- Overview
- Impact of AI on Key Industry Verticals
- Pharmaceutical and Biotech Companies
- Hospitals and Cardiology Centers
- Payers and Healthcare Systems
- Contract Research Organizations (CROs)
- AI Impact on Cardiovascular Drugs Value Chain
- Research and Development (R&D)
- Clinical Trials and Patient Recruitment
- Manufacturing and Supply Chain
- Commercialization and Market Access
- Post-Market Surveillance and Patient Monitoring
- Overview
- Key Spending in AI in the Cardiovascular Drugs Industry
- Abbreviations Used in the Report
Table 1: Recent Investments in AI in Cardiovascular Drugs Industry, 2024-2025
Table 2: Major AI Investments or Spending by Leading Cardiovascular Drugs Companies, 2024-2025
Table 3: Abbreviations Used in This Report
List of Figures
Figure 1: Application of AI in Cardiovascular Drugs Value Chain
